Qingdao Central Hospital

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

The Effect of Dapagliflozin on the Short-term Prognosis of Patients With Acute Myocardial Infarction

Phase 4

Recruiting

Conditions: Myocardial Infarction
Diabete Type 2
Glucose Intolerance

Interventions: Drug: Placebo
Drug: Dapagliflozin 10mg/Tab

First Posted Date: 2021-09-20

Last Posted Date: 2023-09-21

Lead Sponsor: Qingdao Central Hospital

Target Recruit Count: 300

Registration Number: NCT05050500

Locations: 🇨🇳
Mengmei Li, Qingdao, Shandong, China

Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Metastatic Non-Small Cell Lung Cancer

Phase 2

Recruiting

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Osimertinib Oral Tablet

First Posted Date: 2021-07-23

Last Posted Date: 2023-03-29

Lead Sponsor: Qingdao Central Hospital

Target Recruit Count: 20

Registration Number: NCT04974879

Locations: 🇨🇳
Qingdao Central Hospital, Qingdao Cancer Hospital, Qingdao, Shandong, China

Tyrosine Kinase Inhibitors in Metastastic Adenoid Cystic Carcinoma

Phase 2

Recruiting

Conditions: Carcinoma, Adenoid Cystic

Interventions: Drug: EGFR-TK Inhibitor

First Posted Date: 2021-07-23

Last Posted Date: 2023-03-29

Lead Sponsor: Qingdao Central Hospital

Target Recruit Count: 20

Registration Number: NCT04974866

Locations: 🇨🇳
Qingdao central Hospital, Qingdao, Shandong, China

Maintenance Therapy for Small-cell Lung Cancer

Phase 2

Completed

Conditions: Progression Free Survival

Interventions: Drug: cis Platinum, etoposide, S1

First Posted Date: 2018-12-10

Last Posted Date: 2023-03-29

Lead Sponsor: Qingdao Central Hospital

Target Recruit Count: 90

Registration Number: NCT03769935

Locations: 🇨🇳
Qingdao Central Hospital, Qingdao Cancer Hospital, Qingdao, Shandong, China

Study of Irinotecan,Oxaliplatin, and S1 in Patients With Advanced Pancreatic Cancer

Phase 2

Completed

Conditions: Overall Survival

Interventions: Drug: Irinotecan,Oxaliplatin, and S1

First Posted Date: 2018-10-31

Last Posted Date: 2023-03-29

Lead Sponsor: Qingdao Central Hospital

Target Recruit Count: 47

Registration Number: NCT03726021

Locations: 🇨🇳
Qingdao Central Hospital, Qingdao, China

CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell Transplantation

Not Applicable

Conditions: Leukemia, B-Cell
Lymphoma, B-Cell
Minimal Disease, Residual

Interventions: Biological: CD19-targeted CAR-T cells

First Posted Date: 2018-06-21

Last Posted Date: 2018-07-02

Lead Sponsor: Qingdao Central Hospital

Target Recruit Count: 20

Registration Number: NCT03564977

Locations: 🇨🇳
Qingdao Central Hospital, Qingdao, Shandong, China

Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Progression Free Survival

Interventions: Drug: Osimertinib
Drug: docetaxel, bevacizumab

First Posted Date: 2016-11-09

Last Posted Date: 2018-02-14

Lead Sponsor: Qingdao Central Hospital

Target Recruit Count: 147

Registration Number: NCT02959749

Locations: 🇨🇳
Qingdao Central Hospital, Qingdao Cancer Hospital, Qingdao, Shandong, China

Weekly Use First-generation EGFR-TKI in the Treatment of EGFR-TKI Acquired Resistance Non-small Cell Lung Cancer (NSCLC)

Completed

Conditions: EGFR-TKI Resistant Mutation

Interventions: Other: history data

First Posted Date: 2015-10-14

Last Posted Date: 2018-02-14

Lead Sponsor: Qingdao Central Hospital

Target Recruit Count: 30

Registration Number: NCT02575560

Locations: 🇨🇳
Qingdao Central Hospital, Qingdao, Shandong, China

Radiotherapy Alternates Human Epidermal Growth Factor 2 (Her2) Expression in Human Breast Cancer

Completed

Conditions: Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

First Posted Date: 2013-09-04

Last Posted Date: 2023-03-29

Lead Sponsor: Qingdao Central Hospital

Target Recruit Count: 5

Registration Number: NCT01934478

Locations: 🇨🇳
Qingdao Central Hospital, Qingdao Cancer Hospital, Qingdao, Shandong, China

Sorafenib in Liver Function Impaired Advanced Hepatocellular Carcinoma

Phase 2

Completed

Conditions: Liver Cancer

Interventions: Drug: Sorafenib
Other: Best Supportive Care

First Posted Date: 2013-08-30

Last Posted Date: 2018-02-14

Lead Sponsor: Qingdao Central Hospital

Target Recruit Count: 86

Registration Number: NCT01932385

Locations: 🇨🇳
Qingdao Central Hospital, Qingdao Cancer Hospital, Qingdao, Shandong, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy